DPP-4 inhibitor | Comparator | Observation period | Population | Result | Citation |
---|---|---|---|---|---|
Sitagliptin | None | 12Â weeks | T2D | Improved FMD | Kubota Y, et al. J Korean Med Sci. 2012 |
Sitagliptin | Voglibose | 6Â weeks | T2D (men) | Decreased FMD | Ayaori M, et al. J Am Heart Assoc. 2013 |
Alogliptin | (cross-over) | Post-prandial 8Â h | Healthy volunteers | Improved FMD | Noda Y, et al. Cardiovasc Diabetol. 2013 |
Sitagliptin | Conventional therapy | 6Â months | Uncontrolled T2D and CAD | Improved RHI | Matsubara J, et al. Circ J. 2013 |
Sitagliptin | Placebo | 12Â weeks | Newly diagnosed IGT or T2D with ACS | No change in RHI | Hage C, et al. Diab Vasc Dis Res. 2014 |
Sitagliptin | Voglivose | 12Â weeks | Uncontrolled T2D | Improved FMD | Nakamura K, et al. Cardiovasc Diabetol. 2014 |
Teneligliptin | None | 3Â months | T2D | Improved FMD | Hashikata T, et al. Heart Vessels. 2016 |
Trelagliptin | None | 12Â weeks | T2D | No change in FMD | Ida S, et al. Cardiovasc Diabetol. 2016 |
Sitagliptin | Conventional therapy | 24Â months | T2D | No change in FMD | Maruhashi T, et al. Cardiovasc Diabetol. 2016 |
Not specific | Conventional therapy | 12Â months | T2D | Improved FMD | Leung M, et al. Diab Vasc Dis Res. 2016 |
Linagliptin | Placebo | 12Â weeks | T2D | FMD tended to improve | Baltzis D, et al. J Clin Endocrinol Metab. 2016 |
Linagliptin | Placebo | 4Â weeks | T2D | Improved renal endothelial function | Ott C, et al. Diabetologia. 2016 |
Linagliptin | Glimepiride | 4Â weeks | T2D (no history of ASCVD) | No change in FMD | Jax T, et al. Cardiovasc Diabetol. 2017 |
Saxagliptin | Metformin | 12Â weeks | Newly diagnosed T2D | Improved FMD | Li F, et al. Exp Clin Endocrinol Diabetes. 2017 |
Linagliptin | Metformin | 16Â weeks | Uncontrolled T2D | Improved FMD | Shigiyama F, et al. J Diabetes Investig. 2017 |
Vildagliptin | Metformin | 12Â weeks | T2D | No change in FMD | Kitao N, et al. Cardiovasc Diabetol. 2017 |
Saxagliptin | Metformin | 12 months | T2D | Improved FMD | Dell’Oro R, et al. High Blood Press Cardiovasc Prev. 2017 |
Linagliptin | Voglibose | 12Â weeks | Untreated and early stage T2D | Improved RHI | Koyama T, et al. Heart Vessels. 2018 |
Linagliptin | Placebo | 12Â weeks | T2D and CAD | No change in FMD | Tripolt NJ, et al. Cardiovasc Diabetol. 2018 |
Saxagliptin | None | 3Â months | T2D | Improved FMD | Kajikawa M, et al. Sci Rep. 2019 |
Vildagliptin | Glibenclamide | 12Â weeks | T2D and HT without ASCVD | No change in RHI | Cosenso-Martin LN, et al. Diabetes Metab Syndr Obes. 2020 |